Apheon Bioscience specializes in research and development to support life sciences research through recombinant molecular biology technologies. Apheon Bioscience is committed to helping large and small organizations identify novel disease biomarkers to advance first-in-class immunotherapies.  Apheon Bioscience offers affinity-based tumor antigen and biomarker discovery services that simultaneously provide therapeutic lead compounds. Other areas of research include the development of recombinant immune-particles to enhance complex immunoselection procedures and for precision diagnostics. We are also utilizing our platform for synthetic biology applications by creating novel abzyme (antibody-enzymes) capable of boosting catalytic enzymatic activity.  We offer all our goods and services to assist academic laboratories and life sciences companies.  Our mission is to streamline and boost research productivity in a cost-effective manner to help drive discovery.  We welcome partnerships to develop immunotherapies for diseases with unmet medical needs. Our affinity-based antibody development platform profiles disease states based on antigenicity and provides both the biomarker target and corresponding therapeutic lead all-in-one. Lead compounds can be reversed engineered into recombinant human monoclonal antibodies, CAR-T therapy, or converted into antibody drug conjugates (ADC).  The platform can also be deployed for precision medicine serving as a diagnostic to guide combination treatment decisions.
 
Please visit us today to see how we can help propel your research and development needs in a more cost-effective manner.

Apheon Bioscience

Org chart

Teams

Offices